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Abstract 
The HER2 proto-oncogene, a member of the epidermal growth factor 
receptor family, is over expressed in 20-30% of breast cancers.  Genistein, the 
main soy isoflavone, interacts with estrogen receptors and it is also a potent 
tyrosine kinase inhibitor. Previously, our lab found that genistein delayed 
mammary tumor onset in transgenic mice that over express HER2 gene.  Our 
goal was to define the mechanism through which genistein affects mammary 
tumorigenesis in HER2 over-expressing mice. We hypothesized that genistein 
inhibits HER2 activation and expression by both ER-dependent and ER-
independent mechanisms.  Genistein inhibited total HER2 protein expression and 
tyrosine phosphorylation in BT-474, an ERα (-) and ERβ (+) human breast 
cancer cell line, however, E2 had no effect.  Taken together, these data suggest 
that genistein has an ER-independent inhibitory effect, presumably, through 
tyrosine kinase inhibition activity.   
 Although E2+ER and over-expression of HER2 can promote mammary 
tumorigenesis, an inverse relationship between ER expression and HER2 over-
expression has been found in human breast cancer.  We cloned a 500bp 
promoter region upstream of the transcription initiation site.  At low doses, 
genistein mimicked E2 and down-regulated HER2 promoter reporter in BT-474 
cells when co-transfected with ERα but not with ERβ.  However, at high doses, 
genistein inhibition was independent on ERα.  In conclusion, genistein acts 
through ERα at low doses and independently from ERα at high doses, and 
through a combination of these two pathways, genistein regulates HER2 protein 
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expression, tyrosine phosphorylation and HER2 promoter activity.  These data 
support genistein’s chemo-prevention and potential chemo-therapeutic roles in 
breast cancer. 
INTRODUCTION 
Breast cancer is the most common cancer and is the second leading 
cause of cancer death among women in the United States.  There are two 
important receptors whose expression are used as predictive factors in breast  
cancer; estrogen receptor alpha (ERα) and HER2  receptor (ErbB2, neu) [1].  
The American Society of Clinical Oncology has recommended the assessment of 
HER2 in all breast tumors, either at the time of diagnosis or recurrence [2].   
 
HER2 is the second member of the Human Epidermal Growth Factor 
Receptor Family (EGFR) which is composed of 4 members; HER1, HER2, HER3 
and HER4.  The HER2 receptor gene maps to chromosome 17q21 and is a 1255 
amino acid, 185kd trans-membrane glycoprotein [3].  All four HER receptors are 
composed of an extra-cellular ligand binding domain, transmembrane lipophillic 
domain, and an intracellular domain with tyrosine kinase catalytic activity [3].  
Although HER2 does not have known ligands,   HER2 protein has an important 
role in normal cell growth and differentiation.  However, over-expression of HER2 
is linked to the development of many human cancers [4].    
 
 HER2 receptor is over-expressed in 20-30% of primary breast cancer 
cases, and its presence can impede the anti-proliferative effect of hormonal 
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therapy [5].  Moreover, a high level of HER2 expression is associated with lymph 
node positive, high nuclear grade, negative hormone receptor status, and high 
proliferative activity [4].  Because HER2 has an important role in tumorigenesis, it 
has been investigated as a target for cancer therapy.  One of these approaches 
is the use of tyrosine kinase inhibitors [6].   It has been found that blockade of 
EGFR function with the EGFR specific tyrosine kinase inhibitor ZD1839 (Iressa) 
inhibits phosphorylation of the HER2 receptor and growth of HER2 over-
expressing breast carcinoma cells.  Moreover, a combined molecular approach 
using a combination of ZD1839 and the HER2 antibody, herceptin, had more 
anti-tumor effectiveness [7] than either approach alone.  Although both HER2 
and ligand activated ERα are growth promoting [8], an inverse relationship was 
found between over-expression of HER2 and expression of ERα in human breast 
cancer specimens [9].  Natural alternatives, like phytoestrogens, that target 
tumorigenesis at multiple molecular sites such as HER2 and ER may be effective 
in breast cancer prevention and/or treatment.   
 
 The phytoestrogen genistein, the main isoflavone in soy, has been 
proposed to be the agent responsible for lowering the rate of breast cancer in 
Asian women [10]. Genistein has been proposed to work through many 
mechanisms [11,12].  It can interact with both estrogen receptors (ERα and 
ERβ), with preference for ERβ, demonstrating both agonist and antagonist 
effects [13,14].  Genistein is also a potent inhibitor of tyrosine kinase [15], and 
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may reduce in vivo tyrosine kinase activity, specifically epidermal growth factor 
(EGF) receptor phosphorylation in rat prostate [16].   
  
 Several lines of evidence indicate that genistein is protective in breast 
cancer.  First, epidemiological studies  have shown that the age-adjusted death 
rates from breast cancer are 2 to 8 fold lower in Asia compared to Western 
countries, suggesting that dietary factors play an important role in reducing 
breast cancer risk in Asian countries [17].  In addition, immigration studies 
showed that first generation Asian immigrants have low rates of breast cancer 
compared to the second and the subsequent generations [18].  Secondly, the 
average daily intake of soy in Asian culture is about 50g per day compared to 1g 
per day in Western culture [18].  Thirdly, many cell culture and experimental 
models provide evidence for genistein’s role in preventing breast cancer 
[reviewed in [19]].  Finally, in previous work, we observed a significant delay in 
mammary tumor development in genistein-treated transgenic mice expressing 
the activated HER2/neu oncogene under the control of mouse mammary tumor 
virus (MMTV) promoter [20].   
 
 The overall goal of our present work is to define the mechanism by 
which genistein affects HER2 activation and gene expression.  Our working 
hypothesis is that genistein transcriptionally regulates HER2 expression 
through estrogen-dependent and estrogen-independent mechanisms.    In 
this manuscript, we found low doses of genistein repress HER2 protein and 
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promoter activation via an ERα-dependent mechanism.  This observation 
provides an explanation for the chemopreventive role of genistein where ERα is 
present in normal breast epithelium.  Furthermore, we also showed that high 
doses of genistein repressed HER2 protein and promoter activation in an ER-
independent mechanism.  The ER-independent inhibition of HER2 transcription 
using high genistein doses could be a potential therapy for HER2 over-
expressing breast cancer patients who usually lack ER expression. 
 
Materials and Methods 
Chemicals 
Genistein was obtained from LC Laboratories (Woborn, MA), dissolved in 
DMSO and stored as 100 mM stocks at -20oC. 17β estradiol and β-tubulin 
antibody (cat #T7816) were obtained from Sigma Chemical Co. (St. Louis, MO). 
The human reactive polyclonal antibodies for ERα (PA1-308) and ERβ (PA1-312) 
were purchased from Affinity Bio Reagents (Golden, CO). The human reactive 
rabbit polyclonal for HER-2 antibodies (cat # sc-284-R) and the human reactive 
rabbit polyclonal for phosphorylated Tyr 1248 HER2 (cat # sc-12352-R) were 
purchased from Santa Cruz Biotechnology, INC.   
Plasmids 
Human HER2 promoter construct was prepared by cloning a 525bp region 
(-495/+30) in relation to the transcription initiation site [21].  XhoI and Hind III 
restriction sites were inserted by using the following primers:  forward primer 
sequence: 5’ ttccagaagatactcgaggggggtcctgga 3’ and reverse primer sequence: 
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5’gctgcccgggggaagcttctggtttctccg 3’.  Amplified DNA products were ligated into 
the basic PGL-3 luciferase vector (Promega, Madison, WI).  After transformation, 
sequences from independent colonies were verified at the DNA core facility of 
the University of Missouri, Columbia. 
ERα and ERβ expression vectors cloned in  pcDNA Zeo 3.1(+) expression vector 
were prepared as described previously [22].   
 
Cell culture and transfection experiments 
BT-474 human breast cancer cells from ATCC were maintained in Hybri-
Care Medium (Modified Dulbecco's medium) supplemented with 10% fetal bovine 
serum.  For transient transfection experiments, BT-474 cells were plated in 24-
well plates in phenol red free medium and charcoal stripped serum for 24 hours 
and transiently transfected using Fugene 6 (Roche).  Cells were transfected with 
5 ng ERα or ERβ plasmids and 400 ng HER2 promoter reporter vector.  After 24 
hours, transfected cells were treated with the assigned treatment for 20 hours.  
Transfection experiments were normalized to co-transfected pRL-SV40 renilla 
vector (Promega, Madison, WI). Luciferase assays were done using the Dual 
Luciferase Assay kit (Promega).  
 
Western Blotting   
  BT-474 cells were washed with cold PBS then lysed in ice-cold buffer (50 
mM Tris-HCL, 150 mM NaCl, I mM EGTA, 1 mM EDTA, 20 mM NaF, 100 mM 
Na3VO4, 0.5% NP-40, 1% Triton X-100, 100 mM PMSF (pH 7.4) with freshly 
 8
added protease inhibitor cocktail on ice for 30 minutes. The cells were scraped, 
collected in microfuge tubes and sonicated for 30 seconds. The cell lysate was 
cleared by centrifugation at 14000 x g for 15 minutes at 4oC and the supernatant 
(total cell lysate) was used or immediately stored at –80oC. The total cellular 
protein concentration was determined by the DC Bio-Rad assay (Bio Rad 
laboratories, Hercules, CA). For Western blotting, 10µg protein was resolved over 
8-12% polyacrylamide gels and transferred to nitrocellulose membranes. 
Membranes were transversely cut according to the molecular weight marker to 
use the upper part to show protein expression for the target protein and the lower 
part was used for analysis of internal control expression (β-actin or β-tubulin).  
Membranes were incubated in blocking buffer (5% nonfat dry milk/1%Tween 20; 
in 20mM TBS, pH 7.6) for two hours at room temperature, then with appropriate 
polyclonal primary antibody overnight at 4oC, followed by incubation with 
secondary antibody horseradish peroxidase conjugate (Amersham Life Science 
Inc., Arlington Height, IL). Bands were detected by chemiluminescence and 
autoradiography using XAR-5 film (Eastman Kodak CO., Rochester, NY).  
 
Results  
Characterization of BT-474 human breast cancer cell line.   
Previously, we have shown that genistein represses cancer development 
in MMTV/neu mice that over-express HER2 [20].  To further understand the 
mechanism of these results, we studied in vitro the effect of genistein on HER2 
expression and activation.  BT-474 human breast cancer cells have been chosen 
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as our model because they over-expresses HER2 protein [23], which was 
confirmed by western blot (figure 1A).  We also characterized BT-474 for ER 
expression [24].  Although BT-474 cells have been reported as ERα (+) cells [25], 
others found weak ERα expression [26], a third group reported BT-474 to be an 
ER negative cell line [27].  Our characterization confirmed that the BT-474 cells 
we used had minimal or negative ERα expression compared to the well known 
ERα (+), HER2(+) ZR75.1 cells and ER(+), HER2 (-) MCF-7 cells (figure 1B).  
Characterization of ERβ expression revealed that BT-474 cells express similar 
amount of ERβ protein as MCF-7 cells (figure 1C).  
 
Genistein, but not 17βestradiol, inhibited HER2 protein expression and 
phosphorylation. 
Genistein has been shown to be effective treatment in inhibiting ER (-) 
breast cancer cell growth [28,29] which is of clinical importance because most of 
HER2 over-expressing breast tumors are ER(-) and resistant to hormonal 
treatment.  We found genistein inhibited BT-474 cell growth while E2 did not 
(data not shown).  
The ability of genistein to regulate proliferation of the over-expressing 
HER2, BT-474 cells suggests that genistein could regulate HER2 expression 
and/or activation.   The effect of genistein on HER2 protein activation and 
phosphorylation was determined in BT-474.  Treatment of BT-474 cells for 5 
days with 0, 1 µM, 10 µM and 25 µM genistein resulted in a significant dose 
dependent inhibition of HER2 protein expression (figure 2A, 2B) and 
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phosphorylation (figure 3A, 3B).  However, treatment with 0, 0.01 nM, 0.1 nM, 1.0 
nM, or 10 nM 17β-estradiol for 5 days did not affect HER2 protein expression 
(figure 2C, 2D) or phosphorylation (figure 3C, 3D).   
Because genistein, but not E2 treatment, repressed HER2 protein 
expression or activation in this ERα negative cell line, we conclude that 
genistein’s inhibitory action is likely through an ER-independent pathway, 
presumably through its ability to act as tyrosine kinase inhibitor. 
 
Role of ERα in the effect of genistein dose response on HER2 promoter 
luciferase construct.   
To determine if genistein can regulate HER2 expression transcriptionally, 
we cloned the minimum active HER2 promoter (-495/+30) [21]  into the luciferase 
reporter vector PGL-3 basic.  This reporter assay system was used to determine 
the effect of genistein on HER2 transcriptional regulation in the absence or 
presence of co-expressed ERα.  BT-474 cells were transfected with the HER2 
promoter luciferase construct with either ERα expression vector or an empty 
vector.  Treatments were added for 20 hours.   
 
At low doses, genistein (0.1 µM, 1.0 µM) mimicked E2 and significantly 
down-regulated HER2 promoter reporter in BT-474 cells co-transfected with ERα 
expression vector (figure 4).  However, at high doses (10µM, 50 µM, 75µM, 100 
µM), genistein generated similar repression on HER2 promoter reporter in both 
the presence and absence of ERα.  In the absence of ERα, a dose dependent 
 11
inhibition of HER2 promoter activity by genistein was observed.  The HER2 
promoter activity was inhibited by 60% at 50µM concentration.  Similar results 
were obtained using COS-1 cells (data not shown).  To our knowledge, this is the 
first evidence that a botanical compound inhibits HER2 promoter activation and 
reveals the role of ERα in its action. 
 
To confirm the role of ERα in mediating the inhibitory effect of genistein on 
HER2 protein activation level, expression of phosphorylated HER2 was 
determined by western blot.   Genistein at 1.0 µM mimicked E2 inhibition of 
HER2 activation when BT-474 cells were co-transfected with ERα (figure 5A and 
5B).   
 
Role of ERβ and genistein on HER2 promoter  
To define the role of ERβ in HER2 promoter and protein activation, BT-
474 cells were transfected with HER2 promoter luciferase construct with ERβ 
expression vector (5, 10 or 20 ng).  Assigned treatments (control, 10 nM E2, or 
1.0 µM genistein) were added for 20 hours.  ERβ had no effect on HER2 
promotor activation as determined by luciferase reporter assays (figure 6A) and 
no effect on HER2 protein activation as determined by western blot (figures 6B 
and 6C). 
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Discussion 
Genistein has been suggested to have a protective role in breast cancer in 
vivo as well as in vitro models [19].  One oncogene that has been shown to be 
inhibited by genistein is the HER2 protein.  In our study, we have shown that 25 
µM genistein for 5 days inhibited total HER2 protein expression in ERα (-) BT-
474 cells by 60% (figure 2A, 2B).   Consistent with our findings, Li et al, 1999 [28] 
showed that 30µM genistein treatment for 3 days inhibited HER2 protein 
expression  in MDA-MB-435 ER(-) human breast cancer cells  by 50%.  They 
focused on the effect of genistein on cell apoptosis in the absence of ERα.  In 
addition, the aim of that study was to determine the effect of genistein on HER2 
protein dynamics as they used HER2 expression vectors.  We took a different 
research approach, providing evidence for transcriptional inhibition of human 
HER2 at the promoter level by genistein and showing the protective role of ERα 
but not ERβ in the BT-474 human breast cancer cell line.   
 
Genistein is a specific inhibitor of tyrosine protein kinase [15] and thereby,  
could inhibit the tyrosine kinase domain in HER2 protein.  We found that 
genistein starting at 1.0 µM concentration significantly inhibited HER2 
phosphorylation after 5 days of treatment (figure 3A, 3B), however, E2 did not 
change HER2 phosphorylation in ERα (-) BT-474 breast cancer cells (figure 3C, 
3D).   Among studies that have been done to show the tyrosine kinase inhibitory 
effect of genistein, Katdare, et al., 2002 [30] showed by immuno-histochemistry 
that 10µM genistein inhibited HER2 protein and tyrosine phosphorylation in 184-
 13
B5/HER cells.  The focus of their research was to show the effect of genistein on 
cell cycle and cell growth.  Although they found that genistein did not inhibit 
EGFR phosphorylation, Dalu et al, 1998 [16] reported that genistein inhibited 
EGFR phosphorylation in the rat dorsolateral prostate.   In addition, Akiyama et 
al. [15] reported significant inhibition of EGF phosphorylation by 1µg/ml genistein 
(equivalent to 3.7µM).   In addition, genistein has been shown to alter protein 
tyrosine phosphorylation in human peripheral blood mononuclear cells  after an 
oral dose of dietary amounts of genistein [31,32].  These ER-independent 
findings suggest that genistein could be used as drug therapy at high dose to 
target HER2 over-expressing tumors that do not express ERα. 
 
At the transcriptional level, AP-2 [33] and Ets binding sites [21] located in 
the HER2 promoter are reported to play an important role in regulation of HER2 
gene expression.  Although E2+ER and over-expression of HER2 can promote 
mammary tumorigenesis, an inverse relationship between ER expression and 
HER2 over-expression has been found in human breast cancer [9].   E2 has 
been found to down-regulate HER2 gene expression through the AP-2 site in 
ERα (+) breast cancer cells [34].  We proposed that at low doses, genistein 
mimics E2 and down-regulates the HER2 promoter through an ERα-dependent 
mechanism.  This model could explain the preventive role of genistein on normal 
mammary gland that already has ERα.  On the other hand, several Ets 
transcription factors are nuclear targets of signaling pathways including the MAP 
kinase pathway which is a downstream target of HER2 activation.  MAP kinase 
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phosphorylates Ets proteins at a particular serine or threonine residues [35].  We 
demonstrated that genistein presumably as a tyrosine kinase inhibitor, inhibited 
HER2 phosphorylation (figure 3A and 3B).  Therefore, we propose that genistein 
at doses high enough to inhibit the tyrosine kinase could inhibit HER2 promoter 
in the absence of ERα.  Because most of HER2 over-expressing tumors are 
ERα-negative, this is likely a good model for treatment.   
 
To determine if genistein can regulate HER2 expression transcriptionally, 
we cloned the minimum active human HER2 promoter (-495/+30) into the 
luciferase reporter vector PGL-3 basic [21].  We demonstrated that at low doses, 
genistein mimicked E2 and significantly down-regulated HER2 promoter reporter 
in BT-474 cells when co-transfected with ERα expression vector.  However, at 
higher doses, there was no significant difference between with and without ERα 
co-transfection.  Surprisingly, our transcriptional study showed ligand-
independent inhibition of the human HER2 promoter when ERα expression 
vector was co-transfected in BT-474 cells.  Both the ligand-independent 
stimulation as well as inhibition has been reported.  The ligand-independent 
stimulation of ERE reporter by wild type ERα has been shown [36].  On the other 
hand, ligand-independent ERα inhibition of cell migration and metastasis has 
been shown in MDA-MB-231 breast cancer cells suggesting a protective role of 
the unliganded ERα [37].  Interestingly, HER2 over-expression has been co-
related to cell migration and metastasis [28] suggesting the role of ligand-
independent inhibitory role of ERα on HER2 gene expression.  In addition, ERα 
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ligand-independent inhibition has also been shown on the ERE luciferase 
reporter in MCF-7 cells when co-transfected with steroid co-repressor MRF-1 
[38].  To locate the E2 inhibitory site in HER2 promoter, an E2-dependent 
inhibition of a 218bp fragment of human HER2 promoter has been shown 
previously in ZR75.1 and SKBR.3 cells but not using the whole promoter [34].   
 
At the HER2 protein activation level, after 20 hours treatment, genistein at 
1.0 µM mimicked E2 and inhibited HER2 phosphorylation when BT-474 was co-
transfected with ERα.  This supports speculation about the role of ERα in 
inhibiting HER2 total protein expression as demonstrated by Russell and Hung 
[27] who proposed that ER might be a negative regulatory factor for HER2 gene 
expression.  Using western blotting, they found that total HER2 protein 
expression was inhibited in MCF-7 and BT-474 co-transfected with ERα 
expression vector when treated with 10nM E2 for 4 days.    
 
The biological interactions between ERs and HER2 are complex.  
Although activation of HER2 down-regulated ER expression in short-term and 
gave rise to an ER (-) phenotype in the long-term [25], it also promotes E2-
independent transcription activity [39].  Conversely, E2 down-regulated HER2 in 
human breast cancer cells [34].  Bai and Giguere [5] have shown differential 
effects of HER2 over-expression on ERα and ERβ.  They showed that 
expression of HER2 leads ERα, but not ERβ, to recruit SRCs (steroid receptor 
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co-activators).   The differential effect of HER2 on ERα versus ERβ could be 
involved in turn, in the different effects of the two ERs on HER2 expression.   
 
In conclusion, our data support our hypothesis that genistein works 
through ERα at low doses and as a tyrosine kinase inhibitor at high doses 
to regulate HER2.  Through a combination of these two pathways, genistein 
regulates HER2 protein expression, tyrosine phosphorylation and HER2 
promoter activity.  This finding could explain the protective role of genistein 
against breast cancer in general and specifically the highly metastatic form that 
over-expresses HER2.  The demonstration of non ER-dependent inhibition of 
HER2 at higher doses, raise the possibility of using this inexpensive natural 
compound, genistein, as single or adjuvant therapy in ERα (-) and HER2 (+) 
breast cancer.   
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Figure legends 
Figure 1 
Characterization of the BT-474 human breast cancer cell line by western blot 
analysis of HER2 (1 A), ERα (1 B) and ERβ (1 C) protein expression. Cell 
extracts were resolved by gel electrophoresis, electro-blotted onto nitrocellulose 
membrane, and immuno-detected. Figure 1A, extracts of MCF-7 and BT-474 
cells. Figure 1B; lane 1, ZR75-1 cell extract as HER2 (+), ERα (+) positive 
control; lane 2, BT-474 cells extract; lane 3, BT-474 tansfected with 10ng ERα 
expression vector; lane 4, BT-474 cells transfected with 20ng ERα expression;  
lane 5, MCF-7 cells as positive control.  Figure 1C, extracts of BT-474 cells and 
MCF-7 cells as positive control. 
 
Figure 2 
Effect of 17β-estradiol and genistein on HER2 protein expression in BT-474 cells. 
Cells were plated in E2 free medium, treated the next day with A) 0, 1, 10, 25 µM 
genistein (2A) or with 0, 0.01, 0.1, 1.0, 10 nM E2 (2C) for 5 days. The meduim 
with treatment was replaced every 3 days.  Figures 2B, and 2D, individual band 
from figures 2A, 2C respectively, were quantitated, and the ratio of HER2 protein 
to the internal control protein in 3 independent experiments is expressed as 
mean ± SEM.  Bars with * are significantly different from the control, p< 0.05. 
Figure 3  
Effect of 17β-estradiol and genistein on HER2 protein activation in BT-474 cells.  
Cells were plated in E2 depleted medium, treated the next day with 0, 1, 10 or 25 
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µM genistein (3A) or with 0, 0.01, 0.1, 1.0 or 10 nM E2 (3C) for 5 days. The 
media with treatment were replaced every 3 days.  In figures 3B, and 3D, 
individual band from figures 3A, 3C respectively, were quantitated, and a ratio of 
HER2 phosphorylated protein to the internal control protein in 3 independent 
experiments depicted graphically as mean ± SEM.  Bars with * are significantly 
different from the control, p< 0.05. 
 
 
Figure 4 
Effect of genistein dose response on HER2 promoter/ luciferase construct in 
presence and absence of ERα in BT-474 cells.  BT-474 cells were transiently 
transfected with 400ng HER2 promoter luciferase construct and 5ng expression 
vector as indicated.  Results are expressed as mean ± SEM from 3 independent 
experiments run in duplicate.  Control/-ERα has been normalized to 1.  
Treatments in the same experiment are taken as ratio to its control.  Data were 
analyzed by one-way ANOVA and pair comparison of means was done by 
multiple t-test comparison.  Means were considered significantly different at p < 
0.05.  Bars with same letters are not significantly different. 
 
Figure 5 
The effect of ERα co-transfection on HER2 protein activation in BT-474 cells. 
 25
(A) Western blot analysis of phosphorylated HER2.  Lysate from transfected BT-
474 and treated with control (0), 10 nM 17β-estradiol (E2), 1.0 µM genistein (G) 
with (+) or without (-) 5 ng ERα expression vector co-transfection for 20 hours. 
 (B) Individual bands were quantitated, and a ratio of HER2 phosphorylated 
protein to the internal control protein in 3 independent experiments is expressed 
as mean ± SEM.  Bar pairs with * are significantly different from its ERα-negative 
control using student t-test, p< 0.05. 
 
 
Figure 6 
Role of ERβ co-transfection on HER2 promoter and protein activation.  A) 
BT-474 cells were transiently transfected with 400ng HER2 promoter luciferase 
construct and ERβ expression vector as indicated.  Results are expressed as 
mean ± SEM from 3 independent experiments each with duplicate samples. B) 
Western blot analysis of phosphorylated HER2.  Lysate from transfected BT-474 
and treated with control (0), 10 nM 17β-estradiol (E2), or 1.0 µM genistein (G) 
with (+) or without (-) ERβ expression vector co-transfection for 20 hours.  C) 
Individual band from figure 6B were quantitated, and a ratio of HER2 
phosphorylated protein to the internal control protein in two experiments done in 
duplicate depicted graphically as mean ± SEM. 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6  
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6B 
 
 
 
 
Figure 6C 
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